Primary Lateral Sclerosis
Conditions
Brief summary
The goal of this clinical trial is to determine if non-invasive electrical stimulation, using an electric stimulator placed on the skin of the patients back and abdomen for 30 minutes can reduce muscle spasms (spasticity) and improve walking function in patients with primary lateral sclerosis. Participants will attend one in-person clinic visit and participate in one telephone interview 24 hours after the treatment. The clinic visit will include pre-intervention, treatment and post-intervention assessments. The assessments will consist of a complete physical exam by the clinic neurologist followed by assessments and scoring of spasticity, deep tendon reflexes, gait quality, gait speed, gait endurance and balance. Patient's will rate their perceived spasticity pre, immediately post and 24 hours post treatment. The treatment involves one 30-minute electrical stimulation session, which includes application of electrode pads to the patients back and abdomen. The patient will lay supine (on their back) with a pillow placed under their knees for comfort. The pads will then be connected to an FDA approved electrical stimulator. The electrical stimulator will be turned on and current adjusted to the individual patient based on small muscle contractions in their legs. Once the current is set, the patient will lay supine for 30 minutes. After 30 minutes, the device will be turned off and electrode pads removed.
Detailed description
Objective: The primary aim of this preliminary pilot study is to assess the clinical effects of transcutaneous electrical stimulation (tES) in reducing spasticity in the lower extremities and increasing mobility in patients with Primary Lateral Sclerosis (PLS). Study population: 6 patients with a confirmed diagnosis of PLS aged 18-90 Design: Each enrolled participant will attend one in-person clinic visit and participate in one telephone interview 24 hours post-treatment. The clinic visit will include pre-intervention, treatment and post-intervention assessments. The assessments will consist of a complete physical exam by the clinic neurologist followed by assessments and scoring of spasticity, deep tendon reflexes, gait quality, gait speed, gait endurance and balance. The patients will rate their perceived spasticity pre, immediately post and 24 hours post treatment. Treatment will include a 30-minute transcutaneous electrical stimulation (tES) session where tES will be applied through two sets of electrodes positioned adjacent to the T11/T12 spinous processes and a second pair of electrodes placed para-umbilically on the lower abdomen. A current-controlled electrical stimulator will be used to deliver charge-balanced symmetrical, biphasic rectangular pulses to the paraspinal electrodes as the anode for the first phase and as the cathode for the second phase of the stimulation phase. Electrode placement will be verified by applying electrical stimulation to elicit mild posterior root-muscle (PRM) contractions in the L2-S2 innervated rectus femoris, biceps femoris, tibialis anterior, and triceps surae muscle group bilaterally with the participants relaxed in the supine position. This will be determined by palpation at the patellar and achilles tendons of both sides. While the participants remain supine, the stimulator will be set to continuous mode to deliver stimulation at a frequency of 50 Hz and pulse width of 400 microseconds, then the stimulation amplitude will be slowly increased from 0 milliamp (mA) to an amplitude that may generate minor paraesthesias (slight tingling sensations) in some individuals in the bilateral L2-S2 lower extremity dermatomes but below the level that elicited posterior motor root (PMR) contraction responses. The stimulation amplitude will be individually assessed and set for each participant, and the stimulation amplitude upper limit will be no more than 90% of the lowest PRM response for each participant. After this 30-minute tES session, the tES unit will be turned off, the electrodes removed, and the participants assessed.
Interventions
While participants are supine with a pillow placed below the knees for comfort, one 30-minute transcutaneous electrical stimulation session will be performed at a frequency of 50 Hz, pulse width of 400 microseconds and individualized amplitude will be completed.
Sponsors
Study design
Eligibility
Inclusion criteria
* Diagnosis of primary lateral sclerosis by the treating neurologist * Ambulatory with or without a assistive device or orthotic
Exclusion criteria
* History of cancer in the lumbar or thoracic spine * History of surgery with hardware in the lumbar or thoracic spine * Acute lower back pathology * Current pregnancy * History of implantable cardiac device * Diagnosis of significant cognitive impairment by the treating physician * History of seizures or diagnosis of epilepsy * Open wound at location of electrodes * Complete loss of sensation at the area of electrode placement
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Modified Ashworth Scale | Baseline (immediately pre-intervention) and immediately post-intervention (within 30 minutes of intervention). | The Modified Ashworth Scale (MAS) is an ordinal scale that ranges from 0 (no increase in muscle tone) to 4 (rigid flexion or extension). Ten muscle groups were assessed bilaterally from 0-4 yielding a possible score of 0-80 where higher values reflect more rigid muscles indicating a worse outcome. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Deep Tendon Reflex Scale | Baseline (immediately pre-intervention) and immediately post-intervention (within 30 minutes of intervention). | 5 point ordinal scale recorded as a number from 0-4 where 2 is normal and any number above or below this is abnormal. The DTR scale was utilized on each participant and assessed bilaterally utilizing the Patellar and Achilles tendons with a total possible score of 0 to 16. |
| 10-meter Walk Test (10MWT) | Baseline (immediately pre-intervention) and immediately post-intervention (within 30 minutes of intervention). | The 10MWT measures gait speed where the time it takes patient to cover a distance of 6 meters is recorded in m/s. |
| 6 Minute Walk Test (6MWT) | Baseline (immediately pre-intervention) and immediately post-intervention (within 30 minutes of intervention). | The 6MWT assesses overall gait function and endurance. The total distance travelled in 6 minutes is recorded in feet. |
| Tinetti Performance Oriented Mobility Assessment | Baseline (immediately pre-intervention) and immediately post-intervention (within 30 minutes of intervention). | 3 point ordinal scale that ranges from 0-2 with a total possible score of 28 that measures gait quality and balance. Higher scores indicate improved gait and balance. Range is 0-28 points. |
| 0-10 Numeric Rating Scale | Baseline (immediately pre-intervention) and immediately post-intervention (within 30 minutes of intervention) and 24-hours post-intervention | Patients will self rate their spasticity on a scale of 0-10 with 0 = no spasticity and 10 = worst possible spasticity. |
Countries
United States
Contacts
Nova Southeastern University
Northeast Regional Medical Center / A.T. Still University
Participant flow
Recruitment details
Participants were recruited as a convenience sample from a university based ALS clinic or via clinicaltrials.gov
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 66 years STANDARD_DEVIATION 8.17 |
| Height | 69.17 Inches STANDARD_DEVIATION 3.19 |
| Region of Enrollment United States | 6 Participants |
| Sex: Female, Male Female | 3 Participants |
| Sex: Female, Male Male | 3 Participants |
| Time since symptom onset (years) | 18.83 years STANDARD_DEVIATION 7 |
| Weight | 165.5 Pounds STANDARD_DEVIATION 24 |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 6 |
| other Total, other adverse events | 0 / 6 |
| serious Total, serious adverse events | 0 / 6 |